Weiss Ratings Reaffirms Sell (E+) Rating for Cerus (NASDAQ:CERS)

Key Points

• Weiss Ratings has reiterated its "sell (E+)" rating for Cerus (NASDAQ:CERS), reflecting ongoing concerns about the company's financial prospects.
• Cerus reported a loss of $0.03 EPS for the latest quarter, missing analysts' expectations, but exceeded revenue projections with $60.1 million.
• Institutional investors collectively own 78.37% of Cerus, with multiple firms increasing their stakes recently, indicating continued interest from major financial players.

Cerus (NASDAQ:CERS - Get Free Report)'s stock had its "sell (e+)" rating reiterated by stock analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Cerus Trading Up 5.0%

NASDAQ CERS traded up $0.08 during mid-day trading on Wednesday, hitting $1.68. The company's stock had a trading volume of 1,251,299 shares, compared to its average volume of 1,663,552. Cerus has a 52-week low of $1.12 and a 52-week high of $2.24. The stock's fifty day simple moving average is $1.35 and its two-hundred day simple moving average is $1.36. The company has a debt-to-equity ratio of 1.01, a current ratio of 2.00 and a quick ratio of 1.35. The firm has a market capitalization of $322.06 million, a P/E ratio of -16.80 and a beta of 1.70.

Cerus (NASDAQ:CERS - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biotechnology company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.01). The firm had revenue of $60.10 million for the quarter, compared to analyst estimates of $51.80 million. Cerus had a negative return on equity of 33.77% and a negative net margin of 9.81%. Cerus has set its FY 2025 guidance at EPS. Research analysts expect that Cerus will post -0.08 EPS for the current year.

Institutional Investors Weigh In On Cerus

Several institutional investors have recently bought and sold shares of CERS. Focus Partners Advisor Solutions LLC lifted its holdings in Cerus by 65.2% in the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 19,930 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 7,866 shares during the last quarter. Bouvel Investment Partners LLC lifted its holdings in Cerus by 1.7% in the 1st quarter. Bouvel Investment Partners LLC now owns 505,020 shares of the biotechnology company's stock valued at $702,000 after acquiring an additional 8,238 shares during the last quarter. Stephens Inc. AR lifted its holdings in Cerus by 8.8% in the 2nd quarter. Stephens Inc. AR now owns 110,294 shares of the biotechnology company's stock valued at $156,000 after acquiring an additional 8,910 shares during the last quarter. Rhumbline Advisers lifted its holdings in Cerus by 5.5% in the 1st quarter. Rhumbline Advisers now owns 251,907 shares of the biotechnology company's stock valued at $350,000 after acquiring an additional 13,112 shares during the last quarter. Finally, Captrust Financial Advisors lifted its holdings in Cerus by 89.7% in the 2nd quarter. Captrust Financial Advisors now owns 31,109 shares of the biotechnology company's stock valued at $44,000 after acquiring an additional 14,709 shares during the last quarter. Institutional investors and hedge funds own 78.37% of the company's stock.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.